PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor
Interventions: DRUG: CVL218
Sponsor: Fujian Cancer Hospital